PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-184.01%
Both yoy net incomes decline, with CRVO at -78.01%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-9.94%
Both reduce yoy D&A, with CRVO at -70.62%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-368.86%
Negative yoy deferred tax while CRVO stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
368.86%
SBC growth of 368.86% while CRVO is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
55.40%
Slight usage while CRVO is negative at -7.48%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
252.95%
Lower AP growth vs. CRVO's 1657.53%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-12.95%
Both reduce yoy usage, with CRVO at -51.12%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
200.11%
Well above CRVO's 100.00%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-85.28%
Both yoy CFO lines are negative, with CRVO at -68287.52%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
80.16%
CapEx growth of 80.16% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.16%
We expand invests by 80.16% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
54.75%
Debt repayment growth of 54.75% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-0.41%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.